Expressing the sense of the House of Representatives that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science.
119-HRES-1285119th CongressIntroduced May 14, 2026Health
Market Probability
No market
Status
Introduced
Committee
Floor Vote
Other Chamber
Signed
Referred to the House Committee on Energy and Commerce.
Sponsor
Rep. DeGette, Diana [D-CO-1](D-CO-1)42 cosponsors
Actions (2)
Referred to the House Committee on Energy and Commerce.
May 14, 2026House floor actions
Submitted in House
May 14, 2026Library of Congress